WAVRE, Belgium — 24 April 2025: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces positive five-year data from the STAR-GLOBAL trial for the ...

Please provide your email address to receive an email when new articles are posted on . Nearly 90% of participants achieved a reduction in IOP of 20% or greater. Endothelial cell density loss was less ...

Please provide your email address to receive an email when new articles are posted on . AbbVie and iSTAR Medical have entered into a strategic alliance to develop and commercialize the MINIject ...

(RTTNews) - AbbVie (ABBV) on Wednesday said it signed an alliance with iSTAR Medical SA, a Belgian medtech firm, to further develop and commercialize iSTAR's MINIject, a minimally invasive glaucoma ...

WAVRE, Belgium, July 10, 2019 /PRNewswire/ -- iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, today announced consistent 18-month ...

STAR-GLOBAL is an extension trial of the initial EU clinical trials investigating the long-term safety and efficacy of MINIject ® in patients with up to five-years of follow-up. Patients implanted ...

iSTAR Medical's MINIject ® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial Five-year safety profile including corneal health confirmed and 38% IOP ...